Pancreatic Cancer Research

ResearcherUniversity of WashingtonNo recent work listed

Jürgen K. Willmann

Matched on ORCID iD 0000-0003-4306-8171; OpenAlex author ID A5021373741. Sources: OpenAlex.

Their work

Papers
10 (first author 1, last author 4)
Trials
0
Grants
0
Labs led
1
Collaborators
29
Papers, trials and grants by year

2012: 2 papers · 2013: 1 paper · 2014: 1 paper · 2015: 2 papers · 2016: 1 paper · 2017: none · 2018: 3 papers

Papers 10

  1. Advances in Diagnostic and Intraoperative Molecular Imaging of Pancreatic Cancer. First author DOI 10.1097/mpa.0000000000001075↗
  2. Thy1-Targeted Microbubbles for Ultrasound Molecular Imaging of Pancreatic Ductal Adenocarcinoma. Last author DOI 10.1158/1078-0432.ccr-17-2057↗
  3. Development and Preclinical Validation of a Cysteine Knottin Peptide Targeting Integrin αvβ6 for Near-infrared Fluorescent-guided Surgery in Pancreatic Cancer. Co-author DOI 10.1158/1078-0432.ccr-17-2491↗
  4. Preoperative Multidetector CT Diagnosis of Extrapancreatic Perineural or Duodenal Invasion Is Associated with Reduced Postoperative Survival after Pancreaticod… Co-author DOI 10.1148/radiol.2016152790↗
  5. Vascular endothelial growth factor receptor type 2-targeted contrast-enhanced US of pancreatic cancer neovasculature in a genetically engineered mouse model: p… Last author DOI 10.1148/radiol.14140568↗
  6. Combining in Vitro Diagnostics with in Vivo Imaging for Earlier Detection of Pancreatic Ductal Adenocarcinoma: Challenges and Solutions. Last author DOI 10.1148/radiol.2015141020↗
  7. Stromal response to Hedgehog signaling restrains pancreatic cancer progression. Co-author DOI 10.1073/pnas.1411679111↗
  8. Detection of pancreatic ductal adenocarcinoma in mice by ultrasound imaging of thymocyte differentiation antigen 1. Last author DOI 10.1053/j.gastro.2013.06.011↗
  9. Pharmacokinetically stabilized cystine knot peptides that bind alpha-v-beta-6 integrin with single-digit nanomolar affinities for detection of pancreatic cance… Co-author DOI 10.1158/1078-0432.ccr-11-1116↗
  10. Stromal galectin-1 expression is associated with long-term survival in resectable pancreatic ductal adenocarcinoma. Co-author DOI 10.4161/cbt.20842↗

Closest collaborators

The 25 strongest of 29 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Sanjiv Sam Gambhir · 4 shared papers, 2012–2018 · strength 0.30
  2. Richard H. Kimura · 3 shared papers, 2012–2018 · strength 0.20
  3. Willemieke S. F. J. Tummers · 2 shared papers, 2018 · strength 0.18
  4. Rutger‐Jan Swijnenburg · 2 shared papers, 2018 · strength 0.18
  5. Alexander L. Vahrmeijer · 2 shared papers, 2018 · strength 0.18
  6. Teresa A. Brentnall · 4 shared papers, 2012–2015 · strength 0.18
  7. Lotfi Abou‐Elkacem · 2 shared papers, 2018 · strength 0.17
  8. R. Brooke Jeffrey · 2 shared papers, 2015–2016 · strength 0.13
  9. Ru Chen · 3 shared papers, 2012–2015 · strength 0.13
  10. Marybeth A. Pysz · 3 shared papers, 2012–2015 · strength 0.12
  11. Bert A. Bonsing · 1 shared paper, 2018 · strength 0.10
  12. Bhavik Natvar Patel · 1 shared paper, 2016 · strength 0.07
  13. Eric W. Olcott · 1 shared paper, 2016 · strength 0.07
  14. Stephanie T. Chang · 1 shared paper, 2016 · strength 0.07
  15. Paul F. Laeseke · 1 shared paper, 2015 · strength 0.06
  16. E. Scott Seeley · 1 shared paper, 2015 · strength 0.05
  17. Anson W. Lowe · 1 shared paper, 2013 · strength 0.03
  18. Kira Foygel · 1 shared paper, 2013 · strength 0.03
  19. Yves Boucher · 1 shared paper, 2014 · strength 0.03
  20. Vikram Deshpande · 1 shared paper, 2014 · strength 0.03
  21. Philip A. Beachy · 1 shared paper, 2014 · strength 0.03
  22. Nabeel M. Bardeesy · 1 shared paper, 2014 · strength 0.03
  23. Rushika Miriam Perera · 1 shared paper, 2014 · strength 0.03
  24. John J. Lee · 1 shared paper, 2014 · strength 0.03
  25. Christopher L. Wolfgang · 1 shared paper, 2012 · strength 0.03

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.